Novartis' revenue 2007-2021

In 2021, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to 51.6 billion U.S. dollars. This is a significant increase - around three billion U.S. dollars - compared to the year before.

Novartis’ revenue by segment

Between 2014 and 2021, the multinational corporation, based in Basel, Switzerland, generated the bulk of its revenue through brand name pharmaceuticals (innovative medicines): in 2020, the company made 42 billion U.S. dollars from this segment. In the same year Novartis generated close to one fifth of its revenue from its generic drug division (Sandoz).

Competitor Sanofi

Another global leader in the world of healthcare and pharmaceuticals is Sanofi, which is based in Paris, France. In 2020, the French company generated about 36 billion euros' worth of revenue. That same year, the majority of Sanofi’s revenue was earned through pharmaceuticals (roughly 25.7 billion euros), while the vaccine business segment generated around six billion euros.